We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$186M
AUM Growth
+$24.6M
Cap. Flow
+$12.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
43.12%
Holding
83
New
10
Increased
18
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$4.09M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$2.82M
4
SAGE
Sage Therapeutics
SAGE
+$2.79M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.06M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.85M
2
QURE icon
uniQure
QURE
+$1.68M
3
PODD icon
Insulet
PODD
+$1.64M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$1.48M
5
ONC
BeOne Medicines Ltd
ONC
+$961K

Sector Composition

Rank Sector Weight
1 Healthcare 92.53%
2 Miscellaneous 7.1%
3 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$24.9M 13.42%
296,000
+33,879
+13% +$2.82M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$7.59M 4.09%
100,691
+24,691
+32% +$1.74M
ATRC icon
3
AtriCure
ATRC
$2.47B
$7.1M 3.82%
389,145
+5,000
+1% +$99K
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
$6.98M 3.76%
116,770
– –
ARGX icon
5
argenx
ARGX
$64B
$6.02M 3.24%
95,396
+55,396
+138% +$1.81M
ONC
6
BeOne Medicines Ltd
ONC
$41.5B
$6M 3.23%
61,349
-10,500
-15% -$961K
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.51B
$5.86M 3.16%
1,193,228
– –
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$5.37M 2.89%
134,147
+81,647
+156% +$3.14M
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
$5.24M 2.82%
216,119
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.3B
$4.99M 2.69%
124,639
+52,413
+73% +$1.91M
IMMU
11
DELISTED
Immunomedics Inc
IMMU
$4.91M 2.65%
304,000
-156,451
-34% -$1.85M
DXCM icon
12
DexCom
DXCM
$34.3B
$4.76M 2.57%
332,000
+102,000
+44% +$1.33M
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$4.74M 2.55%
+28,800
New +$2.79M
VBIV
14
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$4.26M 2.29%
+33,267
New +$4.09M
NBIX icon
15
Neurocrine Biosciences
NBIX
$15.7B
$4.23M 2.28%
54,508
– –
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
$3.96M 2.13%
346,013
– –
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$868M
$3.82M 2.06%
98,348
+54,000
+122% +$2.06M
LKFT
18
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.71M 2%
39,609
+8,000
+25% +$757K
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
$3.32M 1.79%
361,164
-73,836
-17% -$631K
MGNX icon
20
MacroGenics
MGNX
$263M
$2.93M 1.58%
154,200
– –
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.89M 1.56%
22,371
-1,381
-6% -$129K
IBB icon
22
iShares Biotechnology ETF
IBB
$10.5B
$2.79M 1.5%
26,100
– –
ACHN
23
DELISTED
Achillion Pharmaceuticals
ACHN
$2.73M 1.47%
948,272
+230,000
+32% +$836K
BEAT
24
DELISTED
BioTelemetry, Inc.
BEAT
$2.63M 1.42%
88,100
+38,100
+76% +$1.1M
VYGR icon
25
Voyager Therapeutics
VYGR
$218M
$2.61M 1.4%
157,000
+39,741
+34% +$681K
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, DAFNA Capital Management held 83 positions worth $186M, up 15% from $161M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management deployed $12.5M of net new capital in Q4 2017, opening 10 new positions and adding to 18 existing holdings. Its largest new stake was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.85M trimmed.

  • DAFNA Capital Management's largest Q4 2017 buy was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.
  • DAFNA Capital Management added most to Zogenix, Inc. in Q4 2017, an estimated $3.14M increase.
  • DAFNA Capital Management's biggest Q4 2017 reduction was Immunomedics Inc, cutting an estimated $1.85M.
  • DAFNA Capital Management fully exited uniQure in Q4 2017, selling an estimated $1.68M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $186M portfolio in Q4 2017.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q4 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $186M.

Based on DAFNA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.